Cannabis Law Report

SEPTEMBER 23, 2022

Going forward, MAPS will focus on advocating for psychedelic policy reform to include state funding for public education, harm reduction, and unarmed crisis response services. On the heels of the update about SB 519 was news of Governor Gavin Newsom vetoing another proposed piece of drug policy legislation sponsored by Senator Wiener.

Decriminalization 52

Decriminalization Advocacy Research and Development Education 52

Cannabis Law Report

JUNE 14, 2022

PAREA is coming together to address those challenges and provide evidence-based policy recommendations and expertise to the EU policymakers. More details: Tadeusz Hawrot, PAREA Founder and Policy Lead: tadeusz@parea.science. Find out more about PAREA and register to attend the launch: www.parea.science/launch .

Access 52

Access Therapy Clinical Trials Treatment 52

NORML

JANUARY 4, 2019

Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. Pennsylvania.

Legislation 127

Legislation Clinical Trials Research and Development Access 127

Cannabis Law Report

SEPTEMBER 22, 2021

Despite this, the Home Office “fails to act, perpetuating what can be considered the worst research blackout in scientific history,” according to the Conservative Drug Policy Reform Group (CDPRG), of which Mr Blunt is chairman.

Research and Development 52

Research and Development Clinical Trials Treatment History 52

Cannabis Law Report

JANUARY 19, 2022

With his extensive experience in Congress and as a policy advisor on topics including health, technology, and education, we are confident Congressman Moran will be a great asset to IGC especially at a time when we pursue Phase 2/3 human trials on IGC- AD1 on individuals that have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Education Therapy 52

Cannabis Law Report

JULY 29, 2021

With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

The Cannigma

AUGUST 31, 2021

A 2018 research paper in the International Journal of Drug Policy analyzed in-depth interviews carried out with 24 Israeli physicians working in pain medicine, oncology, and family medicine, and found that “physicians discussed contrasting narratives of cananbi, presenting it as both a medicine and non-medicine.”

Education 101

Education Clinical Trials Medicine Policy 101

Veriheal

JANUARY 5, 2023

A randomized, double-blind, cross-over trial of cannabis recently published by Research Gate explored whether or not cannabidiol (CBD) — the primary non-intoxicating constituent of cannabis and hemp — improves or reduces the cannabis safety. . About the Study Into CBD’s Influence on Cannabis Safety.

Clinical Trials 82

Clinical Trials Safety Consumption CBD 82

SpeedWeed

MARCH 18, 2021

Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. for the production of cannabis used in federally-regulated clinical trials. Research quality” cannabis sparked earlier controversy.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. Feduccia et al.,

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States , and a lack of safety for the use of the drug under medical supervision. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JULY 13, 2019

clinical trials have been made by Members of Parliament. After months of interviews and weighing-up reams of evidence The House of Commons Health and Social Care Committee has issued its latest report; ‘ Drugs policy: medicinal cannabis’. CBD Testers.co However the problem in the U.K.

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

Cannabis Law Report

FEBRUARY 15, 2019

There is even published research, derived from clinical trials, on the potential uses of cannabinoids to manage seizures and epilepsy, cited the ministries. The ministries asserted that the policies are underpinned by research.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

The Joint Blog

OCTOBER 21, 2020

Due to the updated hemp act being relatively new, lawmakers are still studying and formulating policies that can better improve the industry while regulating it for the safety of users. Although scientific research on this has a long way to go, previous studies and clinical trials have produced promising results.

CBD 36

CBD Legalization Oil Hemp 36

Cannabis Law Report

JUNE 1, 2021

Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding. Cautionary Note on Forward-Looking Statements.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Canna Law Blog

APRIL 17, 2020

When it comes to CBD the, research is limited but a small clinical trial at Colorado State University found that CBD oil reduced seizures in epileptic dogs meaning that it may have similar effects as found in humans. However, stakeholders still need to establish the safety of these products with AAFCO and the FDA.

Pets 58

Pets Hemp CBD Food 58

The Cannigma

JUNE 15, 2021

But the main issue with hemp derived products and their safety is less about the CBD and more about everything else in them. The main safety issues with CBD are drug interactions, and unsafe manufacturing processes due to the unregulated environment. . Sonya Yruel/Drug Policy Alliance). Kevin McGovern/Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Canna Law Blog

NOVEMBER 6, 2021

To acknowledge its impressive safety record and potential for treating depression more effectively than existing therapies, the Food and Drug Administration designated psilocybin a breakthrough therapy in 2018 and 2019 for treating drug-resistant depression and major depressive disorder. Last week in Nature Medicine , I.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Project CBD

FEBRUARY 28, 2023

Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. 17 Excerpted from HerbalGram , the quarterly publication of the American Botanical Council.

CBD 144

CBD Seed-To-Sale Food Access 144

CannaMD

MARCH 8, 2021

Authorizing the department to sample marijuana delivery devices from a dispensing facility to determine safety [p. Journal of Economic Analysis & Policy , and Journal of Drug Issues all report drops in crime following marijuana legalization. 1, line 14]. 1, line 17]. 1, line 19]. 1, line 24]. 1455: Other THC Issues.

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

MAY 1, 2022

The Psychedelic Bar Association (PBA) is an association of attorneys and legal professionals dedicated to solving the novel legal and policy issues impacting the emerging psychedelics sector. The PBA Religious Use Committee provides expertise around the intersections of law, policy, psychedelics, and religion.

Safety 52

Safety History Programs Clinical Trials 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). Recently, the decriminalization of psilocybin (by various cities) has been in the news as an emerging medicine.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues.

Research and Development 52

Research and Development Medicine Access Media 52

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. for various studies, including FDA-approved clinical trials.

DEA 70

DEA Research and Development Cultivation Supply Chain 70

Cannabis Law Report

AUGUST 30, 2019

The National Institute on Drug Abuse published a grant notice to encourage research on the effects of changing US cannabis laws and policies on public health. The campaign is designed to remind citizens that while cannabis use is now legal, operating vehicles while under its influence remains against the law and is a public safety issue.

Banking 45

Banking Research and Development Legislation Programs 45

The Cannigma

MARCH 12, 2021

We’re not going to get over the fact that there’s not the same sort of clinical trial and that type of evidence for cannabis and cannabis treatments in the very near future for various reasons. And in my belief, it should be cannabis, because of the safety profile, number one.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

JULY 15, 2022

“Not just the perimeter security, but also the safety and security onsite is paramount.” We are at the crossroads of good agriculture meets good health care which meets great policy. So without going on to the advertising side of things, very important to have your clinical trials obviously based on products.

Medicine 52

Medicine Patients Media Supply Chain 52

Project CBD

NOVEMBER 11, 2023

So just on safety alone, it’s worth using it. We rate levels of evidence, and a high level may be a controlled randomized clinical trial (RCT), but there are also observational studies. For almost all drugs that we use in medicine, the dangerous dose is not very much higher than the therapeutic dose.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Cannabis Law Report

OCTOBER 20, 2021

s NORML Coordinator Dale Gieringer, Delta-8 has undergone minimal testing in humans, “therefore, little is known about its long-term safety, its consumption at high dosages, or its medicinal effects.” Critics of the policies point to the U.S. According to Calif.’s That will be a big one that the appeals court will need to dive into.”

Hemp 52

Hemp Clinical Trials CBD Legalization 52

Weedistry

FEBRUARY 4, 2019

One of the most common arguments against the efficacy of medical cannabis today is that public policy is outpacing real science. And the safety and efficacy of those drugs aren’t even buttressed by a mountain of anecdotal evidence — unlike cannabis use, which has thousands of years of documentation. That’s simply not true.

Clinical Trials 40

Clinical Trials Pharmaceutical Chronic Pain Safety 40

Cannabis Law Report

JULY 21, 2022

The comprehensive legislation would end federal cannabis prohibition by removing cannabis from the Controlled Substances Act; empower states to create their own cannabis laws; ensure federal regulation protects public health and safety; and prioritize restorative and economic justice .

Safety 52

Safety Legislation Clinical Trials Banking 52

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

OCTOBER 17, 2019

Many of these are meant to address public safety risks, especially for young people. For non-US citizens, Malyshev explains, this can result in a lifetime ban from entry into the US under current policy. alcoholic beverages, caffeine, and tobacco). 2% THC—the United Nations has said it will revisit cannabis under the Single Convention.

Law 40

Law Seed-To-Sale Hemp Recreational 40

NORML

JANUARY 28, 2019

Presidents Barack Obama and Donald Trump have voiced support for state governments deciding their own policies. The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine. So, in seven years why hasn’t Kentucky moved forward?

Data 187

Data Clinical Trials Chronic Pain Medicine 187

Cannabis Law Report

JANUARY 14, 2020

Senior Policy Advisor, Diversion Control Division. Additionally, it would open up medical marijuana policies with “directives to conduct research on the impact of marijuana on the brain, the efficacy of medical marijuana, identification of additional medical benefits and uses of cannabis, and support highway safety research.”.

Clinical Trials 69

Clinical Trials Programs Access DEA 69